title: Inflammatory markers in acute exacerbations of obstructive pulmonary disease: predictive value in relation to smoking history.
abstract: The aim of this study was to investigate the relationship between the effect of emergency treatment and inflammatory markers in patients with acute exacerbations of obstructive pulmonary disease, especially with respect to smoking history. We investigated 50 unselected patients with acute bronchial obstruction. Blood, urine and sputum samples were taken and analysed for eosinophil and neutrophil markers. The patients were observed for at least 2 h and recordings of forced expiratory volume in 1 s (FEV1) were taken. They were re-examined after 1 and 4 weeks. The absolute levels of inflammatory markers did not differ significantly between non- or short-term smokers (< or = 5 pack-years) and long-term smokers (> 5 pack-years) with the exception of myeloperoxidase in serum (S-MPO), which was higher in long-term smokers. The patients with higher levels of eosinophil markers before emergency treatment experienced a greater improvement in lung function. In non- or short-term smokers this relationship was found in blood and urine, whereas in long-term smokers it was seen in sputum. No correlation was found between neutrophil markers and changes in lung function. We conclude that patients with obstructive pulmonary disease with acute exacerbations and high levels of eosinophil markers respond well to treatment.
authors.affiliation: Department of Medical Sciences, Uppsala University, Sweden. inger.dahlen@lungmed.uu.se
authors.forename: I
authors.initials: I
authors.lastname: Dahlén
authors.forename: C
authors.initials: C
authors.lastname: Janson
authors.forename: E
authors.initials: E
authors.lastname: Björnsson
authors.forename: G
authors.initials: G
authors.lastname: Stålenheim
authors.forename: C G
authors.initials: CG
authors.lastname: Peterson
authors.forename: P
authors.initials: P
authors.lastname: Venge
mesh_terms: D000208:Acute Disease; D000318:Adrenergic beta-Agonists / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000420:Albuterol / Q000627:therapeutic use; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D015415:Biomarkers / Q000032:analysis / Q000097:blood / Q000652:urine; D001798:Blood Proteins / Q000032:analysis*; D004359:Drug Therapy, Combination; D004804:Eosinophils / Q000201:enzymology; D005260:Female; D005541:Forced Expiratory Volume; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D016015:Logistic Models; D008168:Lung / Q000503:physiopathology; D008173:Lung Diseases, Obstructive / Q000097:blood* / Q000188:drug therapy / Q000503:physiopathology; D008297:Male; D012907:Smoking / Q000097:blood* / Q000503:physiopathology; D013256:Steroids
chemical_list: D000318:Adrenergic beta-Agonists; D000893:Anti-Inflammatory Agents; D015415:Biomarkers; D001798:Blood Proteins; D005938:Glucocorticoids; D013256:Steroids; D000420:Albuterol